MDR.AX MedAdvisor Limited (ASX) A$0.022 intraday: watch oversold bounce setup

MDR.AX stock trades at A$0.022 intraday as we monitor an oversold bounce trade opportunity. We see the price near its year low A$0.02 and far below the 50-day average of A$0.03, a setup that often triggers short-term bounces. Volume is light at 59,301, raising liquidity risk but also increasing the chance of a sharp rebound on positive flows. For ASX traders in Australia this is a high-risk, short-term strategy focused on technical recovery and strict stops.

MDR.AX stock intraday snapshot

Price action is stable at A$0.022 with a day low of A$0.02 and day high of A$0.02. Market capitalisation is A$14,003,474.00 and shares outstanding are 636,521,545.00. Trailing EPS is -0.11 and the reported PE is -0.20. Average volume sits at 1,383,220.00, versus today’s volume of 59,301.00, which highlights low liquidity and wider bid-ask risk for intraday trades.

MDR.AX stock drivers and recent updates

MedAdvisor Limited provides medication adherence software across Australia, the US and UK and reported earnings on 2026-02-26. Recent financial growth shows FY revenue growth of 24.64% and improved gross profit growth of 87.76% year-on-year. The Healthcare sector YTD performance is -10.12%, which weighs on smaller names like MedAdvisor. Key fundamental positives include a low price-to-sales ratio of 0.22 and cash per share of 0.02, while negatives include negative margins and operating cash flow per share of -0.02.

Technical setup for an oversold bounce in MDR.AX stock

Price sits below the 50-day average A$0.03 and well below the 200-day average A$0.07, meeting classic oversold criteria. The stock is close to its year low A$0.02, creating a tight risk range for short-term longs. On an intraday rebound, first resistance is near the 50-day average at A$0.03. A successful break there could target A$0.04 as a near-term bounce target. Low relative volume today increases slippage risk, so traders should size positions conservatively and use limit orders.

Meyka AI grade and MDR.AX stock valuation

Meyka AI rates MDR.AX with a score out of 100: 69.42 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Valuation metrics show EV/Sales 0.33 and Price/Book -8.09, reflecting negative book value. Current ratio is 1.73, suggesting short-term liquidity is adequate. These grades are not guaranteed and we are not financial advisors.

MDR.AX stock risks and a clear trade plan

Primary risks are persistent losses, thin trading volume, and potential equity dilution. The company posts negative operating margins and interest coverage of -3.38, which increases solvency risk. For an oversold bounce plan we suggest a near-term target of A$0.04 and a stop loss at A$0.018 to limit downside. Use tight position sizing, and consider booking partial profits at the 50-day average around A$0.03.

MDR.AX stock outlook and model projections

Meyka AI’s forecast model projects a near-term bounce target of A$0.04 and a medium-term recovery level of A$0.08 versus the current price A$0.022. The near-term target implies an upside of 81.82%, and the medium-term target implies 263.64%. Forecasts are model-based projections and not guarantees. Traders should treat these levels as scenario targets, not certainties, and re-evaluate on fresh company or sector news.

Final Thoughts

Key takeaways for MDR.AX stock: the share price is A$0.022 intraday and sits near its year low, which fits an oversold bounce strategy for short-term traders. Liquidity is thin with volume at 59,301, so manage order sizes and slippage. Fundamental signals are mixed: price-to-sales is low at 0.22, but EPS is negative at -0.11 and margins remain under pressure. Meyka AI’s forecast model projects a near-term bounce to A$0.04 (+81.82%) and a medium-term level of A$0.08 (+263.64%) versus the current A$0.022. These forecasts are model-based projections and not guarantees. For intraday and short-term traders we recommend strict stops at A$0.018, scaling out near A$0.03–A$0.04, and continuous monitoring of volume and any company updates. See the company site for filings and the ASX for listings, and use Meyka AI’s real-time tools for execution signals.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.